176 related articles for article (PubMed ID: 1360820)
21. Characterisation of a mouse tumour cell line with in vitro derived resistance to verapamil.
Twentyman PR; Wright KA; Fox NE
Br J Cancer; 1990 Feb; 61(2):279-84. PubMed ID: 1968761
[TBL] [Abstract][Full Text] [Related]
22. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
Botling J; Liminga G; Larsson R; Nygren P; Nilsson K
Int J Cancer; 1994 Jul; 58(2):269-74. PubMed ID: 7913083
[TBL] [Abstract][Full Text] [Related]
23. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
Naito M; Tsuruo T
Cancer Res; 1989 Mar; 49(6):1452-5. PubMed ID: 2924298
[TBL] [Abstract][Full Text] [Related]
24. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
25. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.
Naito M; Hamada H; Tsuruo T
J Biol Chem; 1988 Aug; 263(24):11887-91. PubMed ID: 3165378
[TBL] [Abstract][Full Text] [Related]
26. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; Barancík M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
27. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
Sela S; Husain SR; Pearson JW; Longo DL; Rahman A
J Natl Cancer Inst; 1995 Jan; 87(2):123-8. PubMed ID: 7707383
[TBL] [Abstract][Full Text] [Related]
29. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance.
Sparrow RL; Hall FJ; Siregar H; Van der Weyden MB
Leuk Res; 1993 Nov; 17(11):941-7. PubMed ID: 7901453
[TBL] [Abstract][Full Text] [Related]
30. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
[TBL] [Abstract][Full Text] [Related]
31. [The use of verapamil in tests for determining the drug resistance of leukemic blasts].
Mukhammed A; Turkina AG; Al'pidovskiĭ VK; Sidorova TA; Golenko OD; Gerasimova GK
Gematol Transfuziol; 1993 May; 38(5):10-4. PubMed ID: 8034162
[TBL] [Abstract][Full Text] [Related]
32. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
33. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
Tsuruo T
Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
[TBL] [Abstract][Full Text] [Related]
34. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
35. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines.
Fukuda T; Kamishima T; Kakihara T; Ohnishi Y; Suzuki T
Leuk Res; 1996; 20(11-12):931-9. PubMed ID: 9009251
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols.
Beksaç M; Akan H; Koç H; Ilhan O; Ertürk S; Güneyli A; Ikizünal Y; Sardaş OS
Med Oncol Tumor Pharmacother; 1992; 9(2):101-5. PubMed ID: 1364132
[TBL] [Abstract][Full Text] [Related]
37. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato W; Fukazawa N; Suzuki T; Yusa K; Tsuruo T
Cancer Res; 1991 May; 51(9):2420-4. PubMed ID: 1673087
[TBL] [Abstract][Full Text] [Related]
38. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Wessels H; de Witte T
Blood; 1999 Oct; 94(7):2414-23. PubMed ID: 10498614
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Naito M; Tsuge H; Kuroko C; Koyama T; Tomida A; Tatsuta T; Heike Y; Tsuruo T
J Natl Cancer Inst; 1993 Feb; 85(4):311-6. PubMed ID: 7678867
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
